Arbutus Biopharma stock
ABUSNASDAQArbutus Biopharma Corp, HealthcareISIN CA03879J1003
65Score 65 out of 100, Neutral
Price and trend
47 / 100
Price history
−17% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 10% below it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 23% below its 52-week high. Largest decline in 19 years: 97% (March 2014 to October 2019).
Chart figures for advanced users
- SMA 50$4.48
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.48
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.66
- The lowest closing price of the last twelve months.
- Resistance$5.22
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Arbutus Biopharma Corp belongs to the Biotechnology industry (United States) and, with a market value of $798.37M, is number 210 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $14.08M (up 128.2% year on year) and a loss of $33.5M.
- MEQIRI Score 65 out of 100 (Neutral): rank 209 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 100% over the last 12 months, Biotechnology median −93.3%.Profitability 99
- More cash than debtCash $337.49M, financial debt $328K.Stability 56
- Earnings turn into cashFree cash flow 100% of earnings over the last 12 months.Fundamentals 56
Weaknesses
- DilutionShare count up 153% since 2020.Capital allocation 54
- Volatile share priceVolatility 46% a year over the last 12 months.Stability 56
Its standout strengths are valuation and profitability, while technical analysis and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
One-off effect in revenue
In the quarter to 31 Mar 2026, revenue of $179.13M was about 136 times the usual level. P/E, margin, growth and score for the last twelve months depend on it.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
UndervaluedClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue fell 43.5% on the same quarter a year earlier. Revenue has changed sharply in recent years: $14.08M in 2025 after $39.02M in 2022.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 97%, operating −192%, net −238%. Last 12 months: net 100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Mar 2027in 112 days
- Last reported
- 10 Nov 2026EPS reported $0.30 (expected −$0.02)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.740.0%
- Revenue
- $182.2M0.0%
- Earnings per share
- −$0.080.0%
- Revenue
- $4.1M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Arbutus Biopharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 65
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Olema PharmaceuticalsOLMA $812.79M34
- Aura BiosciencesAURA $789.19M42
- ArdelyxARDX $786.8M34
- Prime MedicinePRME $779.92M41
- Attovia TherapeuticsATTO $764.77M46
- Janux TherapeuticsJANX $758.06M33
- DBV TechnologiesDBV.PA $744.68M41
- OmniAbOABI $743.89M54
ETFs that hold Arbutus Biopharma
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 1.95% | 0.49% | €26.29M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.05% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.00% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 20 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.